What Коаксил Treats: Main Uses and Benefits

This medication is approved and primarily prescribed in various countries for the management of serious depressive conditions. It is commonly used in the treatment of Major Depressive Disorder (MDD), where it addresses core affective symptoms, including persistent sadness, emotional instability, and the inability to experience pleasure (anhedonia).

The therapeutic support is often applied in clinical situations involving symptom management difficulties, such as when patients have not adequately responded to conventional antidepressants, or when depression is complicated by a significant element of anxiety and physical symptoms. Clinical contexts where it is considered relevant include managing depressive states in older adults with late-life depression and in patients with co-existing chronic conditions. The drug provides support that helps ease the overall symptom burden, assisting patients during difficult episodes by easing distress.

“The therapeutic approach is relevant for supporting the maintenance of emotional stability and addressing the burden of co-occurring psychological tension and fatigue.”

Quick Fact: Symptom Management in Co-morbid Conditions

It is applied in addressing symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities and supporting general well-being during symptomatic phases.

The eligibility criteria for using Коаксил (Tianeptine sodium) are strictly defined by regulatory authorities to classify populations into allowed, contraindicated, and restricted groups. Use is officially established for adults aged 18 and over, but strict exclusions apply.

Contraindications and Restrictions

Eligibility Status	Population/Condition
Contraindicated	Individuals with known hypersensitivity to tianeptine or those concurrently receiving a Monoamine Oxidase Inhibitor (MAOI).
Not Recommended	Children and adolescents under 18 years of age.
Not Recommended	Individuals who are pregnant or breastfeeding.

Use is subject to mandatory limitations for other groups. Patients with severe renal impairment or severe cirrhosis must have their dosage restricted, as must older adults aged over 70. Additionally, treatment must be suspended 24 to 48 hours before any procedure requiring general anesthesia. Caution is advised for patients with a history of drug or alcohol dependence. These classifications strictly define who can and cannot use the medicine according to official labeling.

Interactions with other medicines and products

Formal Interaction Constraints

The primary and most critical interaction is the formal contraindication of Tianeptine sodium with Monoamine Oxidase Inhibitors (MAOIs), a restriction consistently documented in official regulatory sources. Switching between these treatments requires strict timing rules for safety. A mandatory wash-out period of 14 days is required when discontinuing an MAOI and beginning Tianeptine, while only 24 hours is required for the reverse switch.

Pharmacodynamic and Substance Interactions

Co-administration with CNS Depressants (including sedative medications) carries a documented pharmacodynamic risk due to the potential for additive effects, such as increased sleepiness or respiratory depression. For similar reasons, the consumption of alcohol is not recommended while taking Tianeptine. Furthermore, Tianeptine should be discontinued 24 or 48 hours prior to a scheduled general anesthesia procedure.

Pharmacokinetic Profile and Population Notes

Tianeptine's interaction profile is distinct because its metabolism primarily relies on beta-oxidation rather than the common CYP450 enzyme system, officially minimizing the risk of typical CYP-mediated drug-drug interactions. Regulatory documents also note that Tianeptine's clearance is lower in the elderly and in patients with renal impairment, a pharmacokinetic factor that may necessitate careful use in these populations.

Tianeptine sodium’s mechanism is distinct from classical psychotropics, involving the modulation of the HPA axis and related neuroplastic pathways rather than direct, broad monoamine reuptake inhibition.

Modulation of Glutamatergic and Neurotrophic Pathways

The primary focus is the normalization of glutamatergic signaling, the brain's main excitatory system. Tianeptine acts as a modulator of NMDA and AMPA glutamate receptors, regulating over-activity that correlates with structural changes in specific neuronal pathways. This action initiates a cascade, significantly upregulating neurotrophic factors like BDNF (Brain-Derived Neurotrophic Factor), which increases neuronal tolerance to excitotoxicity and facilitates the restoration of dendritic morphology in the hippocampus.

Atypical Agonism at Opioid and Stress Hormone Systems

Tianeptine is a full agonist at the mu-opioid receptor ( MOR). This interaction triggers downstream signaling cascades, including the mTOR pathway, directly contributing to the neuroplastic cascade. Simultaneously, the drug modulates the HPA axis, the central system for glucocorticoid release. By modulating the hormonal feedback within the HPA axis, Tianeptine impacts systemic homeostatic regulation, modulating downstream effects of glucocorticoids on central CNS structures.

The administration of Коаксил, which contains the active substance Tianeptine sodium, is governed by principles that ensure the consistent presence of the drug. The standard route of administration is oral, utilizing the 12.5 mg tablet formulation.

The standard adult regimen requires a total daily dose of 37.5 mg, which is divided into three separate administrations of 12.5 mg each. This three-times-daily (TID) frequency is a use pattern dictated by the active substance's pharmacokinetic profile. To comply with this schedule, each dose is consistently administered at the beginning of the three main meals (morning, midday, and evening). The tablets are intended to be swallowed whole with a liquid.

Specific modifications exist for particular patient populations. For older adults, defined as subjects over 70 years of age, the total daily intake is restricted to a maximum of 25 mg (two tablets). The same maximum daily dose of 25 mg is also required for patients who present with severe renal insufficiency. No adjustment to the standard dosing regimen is needed for patients with chronic alcoholism, even in the presence of cirrhosis. Tianeptine is typically structured as a long-term use component of a wider management plan, focused on supporting sustained emotional stability.

Research evidence / Overview of Studies for Коаксил

Evidence for Use in Major Depressive Disorder (MDD)

Research has explored the role of Tianeptine through short-term Randomized Controlled Trials (RCTs), which are studies where people are randomly assigned to receive the medication, a placebo, or a standard antidepressant. These studies were primarily conducted to examine how symptoms change over defined time intervals, usually over a period of 6 to 8 weeks in adult patients with non-psychotic Major Depressive Disorder. Researchers monitored outcomes related to symptom intensity or variability using standardized scales.

Meta-analyses, which combine data from multiple RCTs, examined studies that included Tianeptine and standard selective serotonin reuptake inhibitors (SSRIs) as comparators in the short-term research setting for depression. Findings from these combined analyses report patterns of change observed across the study populations, with data from Tianeptine groups and active comparator groups being monitored for symptom evolution during the acute phase of treatment.

Evidence in Treatment-Resistant Depression (TRD)

Research also examined Tianeptine's use in patients diagnosed with Treatment-Resistant Depression (TRD)—a condition where symptoms persist despite adequate trials of at least two other antidepressant medications. These studies typically involved smaller sample sizes and included exploratory designs, such as open-label trials.

Studies monitored depressive symptom scores and research explored outcomes related to systemic or functional imbalance in these TRD research scenarios, focusing on changes measured during the short study period. Evidence quality varies across studies, and the results apply only to the populations studied, providing context but not individual predictions.

Limitations and Areas of Research Uncertainty

The research base for Tianeptine is characterized by several key limitations. A significant portion of the core evidence, particularly the comparative RCTs, are older studies, meaning they predate the availability of many current standard-of-care treatments. Comparative evidence is lacking for many newer antidepressants, and data for long-term outcomes remain insufficient, meaning the full duration of its effect is not well characterized.

Furthermore, governmental health authorities in some major markets have noted concerns related to dependence and misuse potential, which has prevented the drug's approval in those regions. This regulatory context highlights where data are still emerging and limits the ability to compare Tianeptine to treatments widely available across all global markets.

Key Studies & References

1. Efficacy, tolerability and safety of tianeptine in special populations of depressive patients (elderly and comorbid alcohol addiction)
2. Tianeptine for Treatment Resistant Depression (Trial Registration)

Common questions about Коаксил (FAQ)

Q: Does Коаксил interact with alcohol?

Regulatory documents state that an interaction with alcohol has not been established in clinical studies. However, official information generally recommends avoiding the consumption of alcohol while taking this medication. This is a common precaution for psychoactive medicines.

Q: Can I take Коаксил if I am pregnant or breastfeeding?

Official product information advises against the use of Коаксил during pregnancy due to a lack of sufficient clinical data on safety. It is also advised not to use the medicine while breastfeeding, as it is not known whether the substance passes into breast milk.

Q: Is Коаксил an antidepressant?

Yes, regulatory sources classify Коаксил (tianeptine) as an antidepressant medication. It is approved for the treatment of depressive episodes, particularly mild, moderate, and severe forms of depression.

Q: What is the active ingredient in Коаксил?

The active ingredient in Коаксил is tianeptine. This substance is classified as an antidepressant, and it works to help regulate mood in the brain.

Q: Can I take Коаксил with MAOIs?

According to the official product information, Коаксил is strictly contraindicated for use simultaneously with non-selective monoamine oxidase inhibitors (MAOIs). There must be a washout period of at least 14 days after stopping a non-selective MAOI before starting Коаксил, and a 24-hour wash-out period after stopping a reversible MAOI before starting Коаксил.

Q: What is the maximum daily dose of Коаксил?

Regulatory documents indicate that the prescribed dosage varies significantly depending on the patient's condition, age, and kidney function. Detailed information on dosage and maximum limits is provided in the official 'How to use' section of the product information, which should be consulted for specific guidance.

Q: Can Коаксил be used to treat anxiety?

While Коаксил is primarily approved for the treatment of depression, the regulatory documents indicate that the medication also demonstrates an anxiolytic effect. This suggests it may help reduce symptoms of anxiety that are associated with a depressive episode.

Q: What should I do if I miss a dose of Коаксил?

Official product instructions provide a specific course of action for a missed dose, generally advising against taking a double dose. This detailed guidance is found within the official product labeling and should be followed for the precise steps required.

Q: Is Коаксил safe for children?

According to regulatory sources, the safety and efficacy of Коаксил in children and adolescents under 18 years of age have not been established. Therefore, the official instructions do not recommend its use in this age group.

Q: How long does it take for Коаксил to work?

Studies and official information indicate that the therapeutic effect of Коаксил may begin to appear within the first few weeks of treatment. As with many antidepressants, the full benefit and symptom improvement typically develop gradually over several weeks of continuous use.

Q: Can Коаксил affect driving ability?

Official product information advises caution regarding activities requiring concentration, such as driving or operating machinery. Like many psychoactive medicines, Коаксил may cause effects like dizziness or drowsiness, which could potentially impair a person's ability to perform these tasks safely.

How to Store and Dispose of Коаксил?

Official regulatory documents define strict storage and disposal requirements for Коаксил (Tianeptine sodium) tablets to ensure product integrity and public safety.

Required Storage Conditions

Condition	Requirement (Official Labeling)
Temperature	Do not store above 30°C (86°F).
Protection	Protect from light and moisture; keep container tightly closed.
Stability	The official shelf-life is 36 months, maintained when stored according to requirements.
Safety	Must be stored out of the sight and reach of children.

Official Disposal Rules

Disposal must adhere to local environmental and pharmaceutical-waste regulations. The product should not be flushed down a toilet or sink, and it is prohibited to allow it to enter sewers or surface water. The preferred method for discarding unused or expired tablets is to utilize an authorized drug take-back program.